Company / Free Cash Flow
Kura Oncology, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$70.7M
FY2025
5-year range
-$125.0M / $133.8M
FY2021-FY2025
Trend
-152.8%
vs FY2024
Sector context
#89 of 194
Health Care
What the data says
At -$71M, Kura Oncology, Inc.'s free cash flow ranks #89 of 194 in the Health Care sector. Improved from -$125M to -$71M over the past 2 years.
Based on SEC 10-K filings.
-$71M in FY2025.
Improved from -$125M to -$71M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#89 of 194 in Health CareTop 46% of 194This company -$70.7M Sector average $470.6M
▼
-115.0% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 152.8% year-over-year.
- Ranks #89 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$70.7M | -152.8% |
| FY2024 | $133.8M | +207.1% |
| FY2023 | -$125.0M | -12.9% |
| FY2022 | -$110.7M | -4.7% |
| FY2021 | -$105.7M | -46.8% |
| FY2020 | -$72.0M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026